RBCs with transmembrane CD4 receptors have potent anti-HIV activity and can be created exvivo in the presence of an electrical field. We conducted a double-blind, randomised dose escalation study in 19 HIV-infected volunteers, to assess the safety, tolerability and anti-HIV activity of autologous RBCs modified by electroinsertion with recombinant transmembrane CD4 (rCD4) protein expressed by a baculovirus vector. Survival of 51chromium-labelled RBC-rCD4 was evaluated in 3 HIV-infected subjects. In two direct Coomb's negative subjects, mean survival t 1/2 was 32.1 and 32.4 days, and in one direct Coomb's positive subject, t 1/2 was 24.2 days. RBC-rCD4 infusion was safe and well-tolerated in all subjects, and survival kinetics of modified RBCs was similar to that of normal RBCs in healthy volunteers. RBCs can be used as carriers for recombinant proteins with therapeutic potential without affecting circulating t 1/2.
|Original language||English (US)|
|Number of pages||1|
|Journal||Clinical pharmacology and therapeutics|
|State||Published - Dec 1 1997|
ASJC Scopus subject areas
- Pharmacology (medical)